AI Integration for Clinical Trial Protocol Feasibility Analysis

AI integration for protocol feasibility connects to three primary data sources within your clinical trial management stack: historical trial data from your CTMS (e.g., Veeva Vault CTMS, Oracle Clinical One), site capability profiles often housed in dedicated study startup platforms or CTMS modules, and patient population databases (e.g., claims data, EHR aggregates, public registries). The integration acts as a pre-study analysis layer, ingesting draft protocol elements—like inclusion/exclusion criteria, visit schedule, and endpoints—via APIs or manual upload, and cross-referencing them against these aggregated data lakes to generate predictive scores.

Implementation typically involves a dedicated feasibility agent that orchestrates this analysis. This agent calls a series of tools: a retrieval-augmented generation (RAG) system over historical protocol documents and outcomes, a predictive model for enrollment rates based on site and indication, and a rules engine for regulatory and operational risk flags. Outputs—such as predicted enrollment timeline, recommended site count, and high-risk protocol elements—are written back to the CTMS as a structured feasibility report object or attached to the study record, triggering workflow notifications for the clinical operations team. This moves feasibility from a manual, spreadsheet-driven process taking weeks to an automated, data-driven analysis completed in hours.

Rollout requires careful governance. Initial models should be deployed in a human-in-the-loop mode, where AI-generated scores and recommendations are reviewed and calibrated by therapeutic area experts. Audit trails must log all data sources used and assumptions made by the AI to ensure reproducibility for regulatory inquiries. Over time, as confidence in the predictions grows, the system can evolve to automatically populate feasibility sections of study startup documents within the eTMF or trigger alerts in project management tools when a protocol's predicted risk score exceeds a defined threshold.

A production implementation connects to three primary data sources via secure APIs and data pipelines: historical trial data from your CTMS (e.g., Veeva Vault CTMS, Oracle Clinical One), site capability profiles from startup or feasibility platforms, and patient population databases (e.g., TriNetX, Flatiron Health). The AI agent, built on a framework like CrewAI or AutoGen, is orchestrated to query these systems, retrieve structured data (enrollment curves, site metrics, population demographics), and run predictive models against the new protocol's inclusion/exclusion criteria and visit schedule. Outputs—predicted enrollment timelines, site activation risks, and patient recruitment bottlenecks—are written back to a dedicated feasibility analysis object within the CTMS or a connected study startup platform, triggering review workflows for clinical operations leaders.

Critical guardrails are implemented at each layer. Data access is controlled via role-based permissions synced from the CTMS, ensuring analysts only see studies and sites within their purview. A prompt management layer enforces that all AI-generated analyses cite their source data (e.g., 'based on 12 similar Phase III oncology studies') and flag confidence intervals. All agent interactions are logged to an immutable audit trail, capturing the source query, data retrieved, model used, and final recommendation for regulatory inspection readiness. Before any analysis is finalized, a human-in-the-loop approval step can be configured in platforms like Veeva, requiring a medical or operational lead to review and sign off on AI-generated feasibility scores.

Rollout follows a phased approach, starting with a pilot on historical, completed protocols to benchmark AI predictions against actual outcomes, tuning models for therapeutic-area-specific variables. The integration is then deployed for active study planning, initially in an advisory mode alongside manual processes. Governance is maintained through a quarterly model review cycle, where new trial data is used to retrain and validate prediction accuracy, and a change control board approves any modifications to the data sources or agent logic. This architecture ensures the AI augments—rather than replaces—expert judgment, providing data-driven insights while maintaining the strict compliance required for clinical development. For related patterns on data integration, see our guide on [/integrations/clinical-trial-management-platforms/ai-integration-for-clinical-trial-data-integration-platforms](AI Integration for Clinical Trial Data Integration Platforms).

Implementation begins by connecting to the CTMS data warehouse (e.g., Veeva Vault CTMS Analytics, Oracle Clinical One reporting APIs) and historical trial databases via secure, read-only service accounts. AI agents are deployed as containerized services that query aggregated, de-identified data—such as site performance metrics, enrollment curves, and country-level regulatory timelines—to train feasibility models. All data flows are logged, and model outputs are stored with full lineage back to source system IDs for auditability, crucial for GxP-aligned environments.

A phased rollout mitigates operational risk. Phase 1 focuses on a single study or therapeutic area, using AI to generate feasibility reports that augment manual analysis. These reports are delivered via a secure dashboard or injected as structured data into the CTMS for side-by-side comparison with traditional methods. Phase 2 integrates AI scoring directly into the CTMS site selection workflow, where the system suggests high-probability sites and flags potential risks (e.g., slow ethics committee timelines) for review by clinical operations. Phase 3 enables predictive scenario modeling, allowing study designers to adjust protocol parameters (e.g., number of sites, inclusion/exclusion criteria) and see projected impacts on enrollment duration.

Governance is enforced through a human-in-the-loop approval layer. Before any AI-generated feasibility score influences a core operational workflow—like activating a site in the CTMS—it must be reviewed and approved by a designated study lead or feasibility expert. All prompts, model versions, and data sources used for each analysis are version-controlled and traceable. This controlled approach allows teams to build confidence in the AI's recommendations while maintaining ultimate human oversight, ensuring compliance with internal SOPs and regulatory expectations for computerized systems in clinical research.